1. 1st 2nd
3rd 4th
June 5-7, 2013 - AgendaTo learn more and register Click Here
Drawing on 3 years of top-notch programming, ACI’s 4th Annual Biosimilars
program remains the industry’s leading legal and regulatory event.
FTC Spotlight: Addressing the Antitrust
Concerns Resulting from Follow-On Legislation
Suzanne Drennon Munck, Counsel for
Intellectual Property, Federal Trade
Commission.
Insights from over 20 companies including a keynote
address from Merck on Branding and Promotional
Consideration for Biosimilars.
Industry insights into when the first applications will
be forthcoming from over two dozen companies
including Eli Lilly, Astra Zeneca, Genentech, and Pfizer.
Keynote Address from: Denise Esposito , Deputy
Associate Director for Policy, Office of Regulatory
Policy ( ORP), CDER Food & Drug Administration
(FDA).
AmericanConference.com/biosimilars